Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AU2-94 (Univ. of South Australia)
- Development stage
- Preclinical
- Lead developer
- University of South Australia
01
Overview
AU2-94 (Univ. of South Australia): sourced facts only. name: "AU2-94 exhibits high selectivity for CDK4 (Ki = 2 nM) over CDK6 (Ki = 279 nM)." [DOI:10.1158/1538-7445.am2024-5701]; target: "AU2-94 exhibits high selectivity for CDK4 (Ki = 2 nM) over CDK6 (Ki = 279 nM)." [DOI:10.1158/1538-7445.am2024-5701]; developer: "1University of South Australia, Adelaide, Australia." [DOI:10.1158/1538-7445.am2024-5701]; stage: "In the colorectal cancer HCT116 (CDK4/6, KRASmut) xenografts, AU2-94 inhibited tumour growth markedly in a dose-dependent manner from 25 to 200 mg/kg without any overt toxicity." [DOI:10.1158/1538-7445.am2024-5701]
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on AU2-94 (Univ. of South Australia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AU2-94 (Univ. of South Australia).